Terguride is currently being evaluated for PAH in a pivotal Phase II trial in Europe.
Representative compounds include apomorphine, N-allylnoraporphine, pergolide, quinpirole, propylnorapomorphine, bromocryptine, trihydroxyaporphine, methylenedioxy-propylnoraporphine, terguride and hydroxyphenyl-N-propylpiperidine.
Terguride is clinically approved in Japan for hyperprolactinemia acting as partial dopamine agonist on the pituitary.
Terguride is approved in Japan for hyperprolactinemia acting as a partial dopamine agonist on the pituitary gland.
We believe that Terguride can provide a significant therapeutic benefit in PAH by inhibiting excess serotonin signalling.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k, -2000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k, -2000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод